نتائج البحث - Yannan Jia

  • يعرض 1 - 4 نتائج من 4
تنقيح النتائج
  1. 1
    Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells

    Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells حسب Yannan Jia, Lina Han, Cassandra L. Ramage, Zhe Wang, Connie C. Weng, Lei Yang, Simona Colla, Helen Ma, Weiguo Zhang, Michael Andreeff, Naval Daver, Nitin Jain, Naveen Pemmaraju, Kapil N. Bhalla, Satu Mustjoki, Peiyi Zhang, Guangrong Zheng, Daohong Zhou, Qi Zhang, Marina Konopleva

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Toll-like receptor alterations in myelodysplastic syndrome

    Toll-like receptor alterations in myelodysplastic syndrome حسب Yue Wei, Sophie Dimicoli, Carlos E. Bueso‐Ramos, Rui Chen, Hui Yang, Donna Neuberg, Sherry Pierce, Yannan Jia, Hong Zheng, Hao Wang, Xia Wang, Minh Nguyen, S. A. Wang, Benjamin L. Ebert, Rafael Bejar, Ross L. Levine, Omar Abdel‐Wahab, M. Kleppe, Irene Gañán‐Gómez, H Kantarjian, Guillermo Garcia‐Manero

    منشور في 2013
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,

    Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity, حسب Dongwen Lv, Pratik Pal, Xingui Liu, Yannan Jia, Dinesh Thummuri, Peiyi Zhang, Wanyi Hu, Jing Pei, Qi Zhang, Shuo Zhou, Sajid Khan, Xuan Zhang, Nan Hua, Qingping Yang, Sebastian Pineda Arango, Weizhou Zhang, Digant Nayak, Shaun K. Olsen, Susan T. Weintraub, Robert Hromas, Marina Konopleva, Yaxia Yuan, Guangrong Zheng, Daohong Zhou

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia

    Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia حسب Qi Zhang, Bridget Riley‐Gillis, Lina Han, Yannan Jia, Alessia Lodi, Haijiao Zhang, Saravanan Ganesan, Rongqing Pan, Sergej Konoplev, Shannon Sweeney, Jeremy Ryan, Yulia Jitkova, Kenneth Dunner, Shaun Grosskurth, Priyanka Vijay, Sujana Ghosh, Charles Lu, Wencai Ma, Stephen E. Kurtz, Vivian Ruvolo, Helen Ma, Connie C. Weng, Cassandra L. Ramage, Natalia Baran, Ce Shi, Tianyu Cai, R. Eric Davis, Venkata Lokesh Battula, Yingchang Mi, Jing Wang, Courtney D. DiNardo, Michael Andreeff, Jeffery W. Tyner, Aaron D. Schimmer, Anthony Letai, Rose Ann Padua, Carlos E. Bueso‐Ramos, Stefano Tiziani, Joel D. Leverson, Relja Popovic, Marina Konopleva

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: